Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_1
1
17%
Ph phase_3
1
17%
Ph phase_4
1
17%
Ph phase_2
2
33%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

unknown117%
withdrawn117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

Aflibercept in Polypoidal Choroidal Vasculopathy

NCT02120950
completedphase_1

Photodynamic Therapy for the Treatment of Vertebral Metastases

NCT02464761
withdrawnphase_2

Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

NCT00457678
completedphase_3

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

NCT01482910
unknownnot_applicable

ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study

NCT01974622
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02120950Phase 4

Aflibercept in Polypoidal Choroidal Vasculopathy

Completed
NCT02464761Phase 1

Photodynamic Therapy for the Treatment of Vertebral Metastases

Completed
NCT00457678Phase 2

Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself

Withdrawn
NCT01482910Phase 3

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Completed
NCT01974622Not Applicable

ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study

Unknown
NCT00140803Phase 2

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6